Nanoparticle/active ingredient conjugates

1. A nanoparticle composition, comprising a nanoparticle, at least one linker bound to the nanoparticle, and at least one therapeutically active substance bound to the nanoparticle via the linker,

wherein the linker is composed of nucleic acids and wherein the linker is thermolabile and is adapted to be melted upon heating of the nanoparticle composition by an alternating magnetic field, wherein the melting occurs in the range of 40° C. to 60° C. which causes, initiates, or substantially enhances separation of the at least one therapeutically active substance from the nanoparticle.

2. The nanoparticle composition according to claim 1 , wherein the linker is a double stranded nucleic acid construct, a double helix, a homo hybrid or a hetero hybrid from DNA-DNA, DNA-RNA, DNA-PNA, RNA-RNA, RNA-PNA or PNA-PNA.

3. The nanoparticle composition according to claim 1 , wherein at least part of the nanoparticle is coated by a protective sheath or a coating.

4. The nanoparticle composition according to claim 3 , wherein the protective sheath or coating comprises amino groups or carboxyl groups.

5. The nanoparticle composition according to claim 1 , wherein the at least one therapeutically active substance is selected from the group comprising antiproliferative, antimigration, antiangiogenic, antithrombotic, anti-inflammatory, antiphlogistic, cytostatic, cytotoxic, anticoagulative, antibacterial, antiviral and/or antimycotic agents.

6. The nanoparticle composition according to claim 5 , wherein the at least one therapeutically active substance is selected from the group comprising actinomycin D, ametantrone, 9-Aminocamptothecin, aminoglutethimide, amsacrine, anastrozole, antagonists of purine and pyrimidine bases, anthracycline, aromatase inhibitors, asparaginase, antiestrogens, bendamustine, bexarotene, biolimus A9, bleomycin, buserelin, busulfan, calicheamicins, camptothecin, camptothecin derivatives, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, cytosine arabinoside, alkylating cytostatics, dacarbazine, dactinomycin, daunorubicin, 5′-deoxy-5-fluorouridine, docetaxel, doxorubicin (adriamycin), doxorubicin lipo, epirubicin, estramustine, etoposide, exemestane, fludarabine, fluorouracil, folic acid antagonists, formestane, gemcitabine, glucocorticoids, goserelin, hormones and hormone antagonists, hycamtin, hydroxyurea, idarubicin, ifosfamide, imatinib, irinotecan, letrozole, leuprorelin, lomustine, maytansinoids, melphalan, mercaptopurine, methotrexate, miltefosine, mitomycins, mitopodozide, antimitotic agents, mitoxantrone, nimustine, oxaliplatin, oxazaphosphorines, paclitaxel, pentostatin, podophyllotoxin derivatives, procarbazine, rapamycin, rhodomycin D, tamoxifen, temozolomide, teniposide, testolactone, thiotepa, thioguanine, topoisomerase inhibitors, topotecan, treosulfan, tretinoin, triptorelin, trofosfamides, vinca alkaloids, vinblastine, vincristine, vindesine, vinorelbine, cytostatically active antibiotics.

7. The nanoparticle composition according to claim 5 , wherein the at least one therapeutically active substance is selected from the group comprising nucleic acids, amino acids, peptides, proteins, carbohydrates, lipids, glycoproteins, glycans or lipoproteins, wherein the aforementioned substances have antiproliferative, anti-migration, antiangiogenic, antithrombotic, anti-inflammatory, antiphlogistic, cytostatic, cytotoxic, anticoagulative, antibacterial, antiviral and/or antimycotic properties.

8. The nanoparticle composition according to claim 1 , wherein the nanoparticle comprises superparamagnetic iron oxides or pure iron having an oxide layer.

9. The nanoparticle composition according to claim 1 , further comprising a sensitizer, radiosensitizer and/or amplifier bound to the nanoparticle for complementing conventional cancer treatment methods.

10. The nanoparticle composition according to claim 1 , further comprising monoclonal antibodies or respectively antibody fragments and/or aptamers bound to the nanoparticle for conveying target finding properties to the nanoparticle composition.

11. A pharmaceutical composition comprising the nanoparticle composition of claim 1 and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is adapted for infusion or injection.

12. A method comprising administering the pharmaceutical composition of claim 11 to a mammal for the treatment of proliferative diseases, cancer and bacterial infections, wherein the administering is an administration to a tumor or infection site, followed by application of an alternating magnetic field.

13. A nanoparticle composition of claim 1 , wherein the nanoparticle is adapted to be heated by an alternating magnetic field.

14. A nanoparticle composition of claim 1 , wherein the separation of the at least one therapeutically active substance from the nanoparticle occurs at a temperature of more than 45° C.

15. The nanoparticle composition of claim 1 , wherein the linker is composed of oligonucleotides.

16. The nanoparticle composition of claim 1 , wherein the therapeutically active substance is siRNA.

17. A nanoparticle composition, comprising a nanoparticle, at least one linker bound to the nanoparticle, and at least one therapeutically active substance bound to the nanoparticle via the linker,

wherein the linker is composed of polypeptides, and wherein the linker is thermolabile and is adapted to be melted upon heating of the nanoparticle composition by an alternating magnetic field, wherein the melting occurs in the range of 40° C. to 60° C. which causes, initiates, or substantially enhances separation of the at least one therapeutically active substance from the nanoparticle.

18. The nanoparticle composition of claim 17 , wherein the linker is composed of polypeptides which form homo dimers or hetero dimers.

19. A nanoparticle composition, comprising a nanoparticle, at least one linker bound to the nanoparticle, and at least one therapeutically active substance bound to the nanoparticle via the linker,

wherein the linker is composed of nucleic acids or polypeptides, and wherein the linker is thermolabile and is adapted to be melted upon heating of the nanoparticle composition by an alternating magnetic field, wherein the melting occurs in the range of 40° C. to 60° C. which causes, initiates, or substantially enhances separation of the at least one therapeutically active substance from the nanoparticle.

20. A method comprising administering the pharmaceutical composition of claim 11 to a mammal for the treatment of cancer, wherein the administering is an intratumoral administration.